Replies to post #255628 on Biotech Values

[dewophile]

Why would checking the value of a CVR the majority of which would only be to on a regulatory milestone in 2 to 3 years help you value an asset more than one that is further along in phase 3 hitting the same target did it occur to you that some of the value in the buyout without the CVR was in fact due the kit inhibitor

[WorstLuck]

share count through the roof.

Bad turn of phrase there, they had a 1:15 reverse split in 2019. Lots of value destruction along the way.